Drug Trial Radar · NCT07898501
SVF Cellular Composition, Secretome, and Responses in Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Sep 30, 2028
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Yonsei UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 27, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, single-center observational study will enroll 20 adults aged 40 to 75 years with Kellgren-Lawrence grade II or III knee osteoarthritis who have already been scheduled for an intra-articular injection of autologous adipose-derived stromal vascular fraction (SVF) as clinical care. The study does not assign treatment, use a control group, or randomize participants. After preparation of the therapeutic SVF, residual adipose tissue will be processed independently with a new disposable kit to obtain research-only SVF. No additional adipose tissue will be harvested for research, and research-only SVF will not be injected. Cellular composition and secretome characteristics of research-only SVF will be measured. Synovial fluid biomarkers will be assessed before injection and at 6 months using the same 12-analyte panel. Patient-reported outcomes and knee radiographs will also be compared between baseline and 6 months. CGBio provides research funding and research-only processing kits without involvement in study conduct, analysis, or publication decisions.
Conditions
- Osteoarthritis, Knee
Interventions
Autologous adipose-derived stromal vascular fraction intra-articular injectionBiological
As clinical care, approximately 200 mL of abdominal lipoaspirate is collected under general anesthesia after tumescent infiltration. SVF is prepared using the CGBio Cell Unit closed automated processing system, concentrated to approximately 5 mL, and injected once into the affected knee. The decision to perform this treatment precedes research enrollment. Research-only SVF is separately prepared from residual adipose tissue using a new kit and is never administered to participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Red blood cell contamination of research-only SVFTime frame: Baseline (procedure day)
- Total nucleated cell count of research-only SVFTime frame: Baseline (procedure day)
- MSC-like stromal progenitor cell compositionTime frame: Baseline (procedure day)
- CD34-positive adipose stromal progenitor cell compositionTime frame: Baseline (procedure day)
- Research-only SVF secretome analyte concentrationsTime frame: Baseline (procedure day)
- Change from baseline in synovial fluid biomarker concentrations at 6 monthsTime frame: Immediately before injection and 6 months after injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yonsei University College of Medicine
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.